Fresenius Kabi completes acquisition of Ivenix, Inc., creating an industry-leading infusion therapies offering in the U.S.

May 4, 2022

Milestone for Fresenius Kabi’s Vision 2026 growth strategy by expanding in MedTech

The combination creates a comprehensive and leading setup of premium infusion therapy products for the benefit of patients, customers, and stakeholders

Significant scale and growth synergies expected

Ivenix, Inc., infusion therapies offering in the U.S.

Fresenius Kabi closed the acquisition of Ivenix, Inc. (“Ivenix”), a specialized infusion therapy company. The transaction was previously announced on March 31, 2022

“Today we are excited to announce Ivenix to join Fresenius Kabi with the successful closing of the transaction. We are moving rapidly in delivering on our growth strategy laid out in Vision 2026,” said Michael Sen, Chief Executive Officer, Fresenius Kabi. “With us expanding in MedTech we will provide state-of-the-art and industry leading offerings in infusion therapy for the U.S. market. All for the long-term benefit of patients and our customers along the continuum of critical and chronical care. The acquisition is an ideal fit both in market offerings as well as competencies as we welcome an outstanding and truly dedicated healthcare and technology team to our global Fresenius Kabi family.”

Ivenix adds a next-generation infusion therapy platform for the significant U.S. market to Fresenius Kabi’s portfolio and provides the company with key capabilities in hospital connectivity and interoperability. This creates new options in the large and growing infusion therapy market. The combination of Ivenix’ leading hardware and software products with Fresenius Kabi’s offering in intravenous fluids and infusion devices will create a comprehensive and leading setup of premium products. This forms a strong, accelerated basis to enable sustainable growth in the high-value MedTech space.

The purchase price is a combination of US$240 million upfront payment and milestone payments, strictly linked to the achievement of commercial and operating targets. The acquisition is expected to be neutral to Group cash earnings per share in 2025 and accretive from 2026 onwards.